United States Patent 8,829,195: Asciminib Claim Scope, Patent Landscape and Generic Entry Risk
US Patent 8,829,195 is a core Novartis composition-of-matter patent covering asciminib and a broad genus of substituted nicotinamide ABL inhibitors. Its most commercially important claims are claim 8, which recites the R-enantiomer of asciminib, and claims 9-15, which cover treatment of CML and ALL with asciminib alone or in combination with approved BCR-ABL tyrosine kinase inhibitors. The patent has an Orange Book-listed term extending into March 2032, subject to the exact FDA-listed expiration date and any applicable patent-term adjustment.[1-3]
The patent creates three principal barriers to generic entry:
- A composition claim covering asciminib itself.
- Broad genus claims that may capture close chemical substitutes.
- Method-of-use claims covering CML and ALL treatment, including combination regimens.
Asciminib received FDA approval in 2021 as Scemblix. FDA granted five-year new chemical entity exclusivity, which expires in October 2026. That regulatory exclusivity ends well before the principal composition patent.[2]
What drug does US Patent 8,829,195 protect?
The patent protects substituted nicotinamide compounds having a nicotinamide core substituted with a pyrazolyl group, a substituted pyrrolidinyl group, and a substituted anilide group. The commercial compound is asciminib, chemically identified as:
(R)-N-(4-(chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)nicotinamide.
Asciminib is an allosteric BCR-ABL1 inhibitor. Unlike ATP-site TKIs such as imatinib, nilotinib and dasatinib, asciminib binds the myristoyl pocket of BCR-ABL1. The product is approved for Philadelphia chromosome-positive CML, including chronic-phase disease in specified previously treated populations and accelerated-phase disease in adults.[2]
Key patent data
| Item |
Data |
| Patent |
US 8,829,195 B2 |
| Title |
Substituted nicotinamide derivatives |
| Patent holder |
Novartis-related applicant and assignee |
| Issue date |
September 9, 2014 |
| Principal product |
Asciminib |
| Brand |
Scemblix |
| Therapeutic class |
Allosteric BCR-ABL1 tyrosine kinase inhibitor |
| FDA approval |
October 29, 2021 |
| NCE exclusivity |
Through approximately October 29, 2026 |
| Orange Book patent term |
March 2032, subject to the FDA-listed expiration date |
| Core commercial claim |
Claim 8 |
| Key use claims |
Claims 9-15 |
| Separate stereochemical compound |
Claim 16, S-enantiomer |
How broad is claim 1 of US 8,829,195?
Claim 1 is a Markush genus claim. It covers compounds of formula (I) meeting defined structural requirements for five substituent regions:
- R1 must be pyrazolyl.
- R2 must be pyrrolidinyl substituted with one R7 group.
- R3 is hydrogen or halo.
- R4 is either pentafluorosulfanyl, represented as -SF5, or a -Y2-CF2-Y3 group.
- Pyrazolyl substituents R6 may include hydrogen, hydroxy, alkyl, alkoxy, cyano, trifluoromethyl, halo, amino and cyclopropyl groups.
- Pyrrolidinyl substituent R7 includes hydroxy, alkyl, halo, amino, aminoalkyl, carboxy, phosphonooxy, cyano and related groups.
The claim therefore covers much more than asciminib. It reaches a chemical class defined by:
- A substituted pyrazole.
- A substituted pyrrolidine.
- A substituted nicotinamide or related heteroaromatic core.
- A restricted set of fluorinated, sulfur-containing or oxygen-containing terminal substituents.
The claim is broad in substituent diversity but narrow in scaffold architecture. A molecule that changes the core connectivity, removes the pyrrolidine, replaces the pyrazole with another heterocycle, or materially changes the R4 substituent may fall outside claim 1 even if it retains allosteric BCR-ABL activity.
R4 creates an important genus boundary
The R4 definition covers either:
- -SF5; or
- -Y2-CF2-Y3, where Y2 is CF2, O or S(O)0-2 and Y3 is hydrogen, halo or selected fluoroalkyl and alkyl groups.
Asciminib uses the chlorodifluoromethoxy substituent, corresponding to an O-CF2-Cl motif. That structure falls squarely within the claimed R4 alternatives.
This limitation is significant for freedom-to-operate analysis. A competing compound with a conventional trifluoromethyl, difluoromethyl, nitrile or nonfluorinated alkoxy substituent may avoid the literal R4 limitation, depending on the full formula and prosecution history.
What do claims 2 and 3 add?
Claims 2 and 3 narrow claim 1 by imposing more detailed positional rules for R6 substituents on the pyrazolyl ring. Substitution attached to a nitrogen atom is limited to a smaller group that includes methyl, hydroxyethyl, fluoroethyl, ethyl and cyclopropyl. Carbon-linked substitution retains a broader set of options, including hydroxy, methoxy, cyano, trifluoromethyl, halo and amino.
The narrowing structure has two effects:
- It reduces the number of covered pyrazole substitution patterns.
- It improves the patent's fallback position if the broadest genus claim is challenged for lack of enablement, written description or novelty.
Claims 2 and 3 appear highly overlapping in the text supplied. Their legal distinction depends on the structural formulas and any limitations shown in the patent drawings, which are not reproduced in the claim text. The formulas should be reviewed before assigning separate chemical scope to the two claims.
What is the scope of claims 4 through 8?
Claims 4 through 7 are dependent compound claims directed to selected species within the genus. The supplied text omits the enumerated chemical structures after "selected from." Their precise scope therefore cannot be mapped from the text alone.
Claim 8 is fully identifiable and is the principal product claim:
(R)-N-(4-(chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)nicotinamide.
This is the asciminib molecule, including pharmaceutically acceptable salts. Claim 8 is a composition-of-matter claim and is substantially stronger against an ordinary generic product than the method claims because a generic manufacturer would need to market the same active ingredient to obtain an ANDA approval for the reference product.
Why claim 8 is commercially important
Claim 8 covers the active pharmaceutical ingredient rather than a particular dosage, indication or formulation. A generic manufacturer cannot avoid infringement merely by:
- Using a different tablet excipient.
- Manufacturing the API by a different process.
- Changing the tablet strength.
- Using a different package.
- Seeking approval for a different CML dosing schedule.
A salt, polymorph or solid form may raise separate issues. Claim 8 expressly covers pharmaceutically acceptable salts, but its treatment of a specific crystalline form depends on the claim language and the scope of any later solid-state patents.
What do claims 9 through 15 protect?
Claims 9-15 are method-of-treatment claims covering asciminib administration to patients with:
- Chronic myeloid leukemia.
- Acute lymphoblastic leukemia.
Claim 9 permits sequential or simultaneous administration with:
- Imatinib.
- Nilotinib.
- Dasatinib.
- Bosutinib.
- Ponatinib.
- Bafetinib.
Claims 10-12 narrow the treatment format. Claims 13-15 add dose ranges:
- Asciminib: 90-130 mg/kg.
- Nilotinib: 10-50 mg/kg.
- Imatinib: 50-200 mg/kg.
The dose limitations appear more relevant to preclinical or experimental regimens than to the approved human Scemblix label, which uses substantially lower human dosing expressed in milligrams rather than kilograms. Their practical infringement value may therefore be narrower than the composition claim.
How enforceable are the combination claims?
The combination claims could be relevant to clinical development, investigator-sponsored studies, combination-label expansion and certain treatment protocols. They are less likely to block generic sale by themselves unless the generic product is labeled for the patented combination or instructions cause users to perform the claimed method.
A generic applicant may attempt a section viii label carve-out for patented methods. That approach is less effective against claim 8 because claim 8 is directed to the compound itself.
What does claim 16 protect?
Claim 16 covers the S-enantiomer:
(S)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)-N-(4-(trifluoromethoxy)phenyl)nicotinamide.
This is structurally distinct from asciminib because it uses:
- The S configuration at the hydroxypyrrolidine stereocenter.
- A trifluoromethoxy phenyl group rather than asciminib's chlorodifluoromethoxy group.
Claim 16 is a separate compound claim. It does not, on its face, expand claim 8's protection of the R-enantiomer of asciminib. Its presence demonstrates that the patent includes specifically claimed stereochemical and substituent variants, not only a single commercial molecule.
When does asciminib lose regulatory and patent exclusivity?
| Protection |
Expected endpoint |
Commercial effect |
| FDA NCE exclusivity |
October 2026 |
ANDA submission becomes possible, subject to other protections |
| US 8,829,195 composition patent |
March 2032 |
Core API protection remains in force |
| Later formulation or solid-form patents |
Potentially later than 2032 |
May delay practical substitution if valid and listed |
| Method-of-use patents |
Indication- and label-dependent |
May be carved out or challenged |
| Biosimilar exclusivity |
Not applicable |
Asciminib is a small molecule, not a biologic |
The principal near-term event is the end of NCE exclusivity in 2026. That date does not imply immediate generic launch. An ANDA applicant would still need to address listed patents and obtain FDA approval.
The core patent's nominal term extends roughly five and a half years beyond NCE exclusivity. A Paragraph IV challenge could accelerate litigation, but a successful challenge would be required before a generic could enter before patent expiration.
What is the Orange Book status of US 8,829,195?
US 8,829,195 is associated with Scemblix's Orange Book patent protection as the principal composition patent. Orange Book listing gives Novartis the ability to receive a certification notice when an ANDA applicant asserts that the patent is invalid, unenforceable or not infringed.[3]
The likely certification scenarios are:
- Paragraph III certification: the applicant accepts that approval will wait until patent expiration.
- Paragraph IV certification: the applicant asserts that the patent is invalid, unenforceable or not infringed.
- Section viii statement: the applicant omits a patented method of use from its label.
A section viii carve-out cannot ordinarily remove a composition-of-matter claim from an ANDA directed to asciminib. It may, however, address claims 9-15 if the relevant leukemia combination use is listed as a protected indication.
Which companies are challenging asciminib exclusivity?
The supplied information identifies no named ANDA challenger, Paragraph IV notice, or US litigation involving US 8,829,195. The public Orange Book and court docket should be treated as the controlling sources for current challenger identity and litigation status.[3,4]
The absence of a named challenger in the supplied record means that no litigation-based early-entry date can be assigned. Generic applicants are likely to evaluate the patent on three principal grounds:
- Validity: written description and enablement challenges against the Markush genus.
- Obviousness: arguments based on prior BCR-ABL inhibitors and disclosed heteroaryl nicotinamide combinations.
- Infringement: attempts to avoid specific R4, stereochemical or salt limitations.
Claim 8 is more difficult to design around than claims 1-3 because it identifies the full commercial molecule. A challenger would normally need to attack validity or establish a noninfringing product distinction, rather than rely on a minor formulation or manufacturing change.
What other patents may affect generic entry?
Asciminib's patent estate should be analyzed as a layered portfolio rather than as US 8,829,195 alone.
Composition patents
US 8,829,195 is the central composition patent. It covers asciminib directly and provides the strongest barrier to an API-equivalent generic.
Solid-state and salt patents
Separate patents may protect:
- Specific crystalline forms.
- Hydrates or solvates.
- Salt forms.
- Particle-size distributions.
- Stability-enhancing forms.
These patents can matter after the core composition patent expires, but their value depends on actual Orange Book listing, validity and whether the generic's API form falls within the claims.
Formulation patents
Formulation patents may cover tablet compositions, excipient combinations, dissolution profiles or dose-specific products. They are weaker than an API patent when the generic can use a noninfringing formulation, but they may restrict substitution for particular strengths or presentations.
Manufacturing patents
Process claims may cover preparation of:
- The nicotinamide core.
- The chiral hydroxypyrrolidine intermediate.
- The chlorodifluoromethoxy aniline component.
- The final coupling and purification steps.
A process patent generally does not prevent sale of API made by an alternative process. It can still create discovery risk if the generic process is similar to the patented route.
Method-of-use patents
Claims 9-15 are directed to CML and ALL treatment, including combination therapy. Method claims may have commercial value for label expansion and combination products but usually present a narrower generic barrier than claim 8.
How strong is the patent estate for Scemblix?
The estate is strong through the composition patent's scheduled 2032 expiration. The strength is highest for direct asciminib copies and lower for structurally modified allosteric BCR-ABL inhibitors.
| Risk area |
Assessment |
| Direct generic asciminib |
High barrier through composition claim 8 |
| Alternative salt |
Requires claim and Orange Book analysis |
| Alternative polymorph |
Depends on separate solid-form coverage |
| Alternative formulation |
Potentially avoidable if no API claim is implicated |
| New allosteric BCR-ABL inhibitor |
Lower direct infringement risk, but genus and doctrine-of-equivalents issues remain |
| Combination therapy |
Moderate, indication-dependent risk |
| Biosimilar competition |
Not applicable |
| Process substitution |
Potentially manageable through a clean-room process design |
The genus claims could support infringement arguments against close analogues, but the actual risk depends on claim construction, prosecution history and the chemical structure of the competing compound. A structurally distinct allosteric inhibitor would not automatically infringe merely because it binds the same myristoyl pocket.
How does asciminib compare with competing CML drugs?
Asciminib competes with ATP-site TKIs including imatinib, nilotinib, dasatinib, bosutinib and ponatinib. Those products have separate patent estates and earlier market entry dates.
| Product |
Active ingredient |
Binding mode |
Relationship to US 8,829,195 |
| Scemblix |
Asciminib |
Myristoyl-pocket BCR-ABL inhibitor |
Directly protected by claim 8 |
| Gleevec |
Imatinib |
ATP-site TKI |
Listed in combination claims 9-15 |
| Tasigna |
Nilotinib |
ATP-site TKI |
Listed in combination claims 9-15 |
| Sprycel |
Dasatinib |
ATP-site TKI |
Listed in combination claims 9-15 |
| Bosulif |
Bosutinib |
ATP-site TKI |
Listed in combination claims 9-15 |
| Iclusig |
Ponatinib |
ATP-site TKI |
Listed in combination claims 9-15 |
| Bafetinib |
Bafetinib |
Investigational ATP-site TKI |
Named in claims 9-12 |
The patent does not protect these competing drugs as standalone products. It covers their use with asciminib in specified treatment methods.
What generic launch scenarios exist for asciminib?
Launch after patent expiration
This is the lowest-risk scenario. An ANDA applicant could pursue approval before the 2032 expiration date but defer commercial launch until the listed composition patent expires.
Paragraph IV launch
A generic applicant could file a Paragraph IV certification and challenge US 8,829,195. Novartis could sue within the statutory period, triggering a 30-month stay of approval under the Hatch-Waxman framework, subject to court action and statutory exceptions.[5]
At-risk launch
An applicant could launch before final resolution after obtaining approval and accepting potential damages and injunction exposure. The commercial incentive would depend on expected sales, litigation strength and the remaining patent term.
Carved-out indication launch
A generic could remove certain combination or ALL uses from its label if FDA and patent-listing requirements permit. This strategy would not avoid claim 8 for the asciminib compound itself.
Key Takeaways
- US 8,829,195 is a core asciminib composition patent.
- Claim 8 directly covers the commercial R-enantiomer of asciminib.
- Claim 1 reaches a broad genus of substituted pyrazolyl-pyrrolidinyl nicotinamide compounds.
- Claims 9-15 cover CML and ALL treatment, including combinations with six named BCR-ABL inhibitors.
- Claim 16 covers a separate S-enantiomer and trifluoromethoxy analogue.
- FDA NCE exclusivity expires in October 2026, while the principal patent extends into March 2032.
- Biosimilar competition is irrelevant because asciminib is a small-molecule drug.
- A generic using the same asciminib API faces the highest infringement risk under claim 8.
- Formulation, solid-form and process patents may create additional barriers, but their effect depends on actual claims and Orange Book listing.
- No named Paragraph IV challenger or litigation outcome is established by the supplied record.
FAQs
Does US 8,829,195 cover Scemblix tablets?
Yes. The patent's principal protection is for asciminib as an active compound. It does not necessarily claim every tablet formulation, excipient system or manufacturing process used for Scemblix.
Can a generic avoid US 8,829,195 by using a different asciminib salt?
Not necessarily. Claim 8 expressly includes pharmaceutically acceptable salts. The specific salt, solid form and claim construction would control.
Does the patent cover asciminib resistance mutations?
The claims cover the compound and specified treatment methods. They do not require a particular BCR-ABL mutation in the patient. The commercial indication and FDA label determine the practical scope of the treatment claims.
Is claim 16 another form of asciminib?
No. Claim 16 recites an S-enantiomer with a trifluoromethoxy substituent, while asciminib is the R-enantiomer with a chlorodifluoromethoxy substituent.
Could a new allosteric BCR-ABL inhibitor infringe the patent?
Yes, if its structure falls within the claimed genus and satisfies every required limitation. Binding to the same myristoyl pocket alone is insufficient to establish literal infringement.
References
- United States Patent No. 8,829,195 B2. (2014). Substituted nicotinamide derivatives. U.S. Patent and Trademark Office.
- U.S. Food and Drug Administration. (2021). Scemblix (asciminib) prescribing information.
- U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Patent and Trademark Office. (2025). Patent Center.
- U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions and Paragraph IV certifications under the Hatch-Waxman Amendments.
